NCT06588218 Effect of Watermelon on Gut and Cardiometabolic Health
| NCT ID | NCT06588218 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida State University |
| Condition | Obesity and Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2024-10-13 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2024-10-13 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are: 1. Will consuming fresh watermelon daily for 6-weeks will improve intestinal barrier health and increase microbiome diversity such as an increased population of beneficial 'probiotic' bacteria when compared to control participants consuming a low-fat snack? 2. Will consuming fresh watermelon daily for six-weeks will improve other health measures, including body-composition, blood pressure, blood vessel function, blood lipid profiles, and measures of inflammation, as compared to control participants consuming a low-fat snack for the same time period?
Eligibility Criteria
Inclusion Criteria: * Between 18 and 30 years old * Ability to speak and read in English * Overweight or Obese Class 1 and 2 (BMI ≥ 25 - 39.9 kg/m2) Exclusion Criteria: * Intake of antibiotics in the last 3 months * Intake of pre/pro/postbiotics in the last 3 months * Current or past (within the last 6 months) user of tobacco, marijuana, or E-cigarette products * Cardiovascular disease (will not exclude for hypertension), gastrointestinal disease (ulcerative colitis, celiac, Crohn's disease, diverticulosis, peptic ulcers, small intestinal bacterial overgrowth, short bowel syndrome), neurological (multiple sclerosis, meningitis, recent stroke) or endocrine disorders (uncontrolled thyroid disorders, growth hormone disorders, adrenal gland disorders, uncontrolled diabetes - A1C greater than 9%). * Food allergy to study foods * Any allergy to melon * Any allergy to the isocaloric snack (gluten) * Regular consumption of watermelon greater than 2 servings / week * Current heavy alcohol use (≥ 15 drinks / week for men, ≥ 8 drinks / week for women * Class 3 Obesity (BMI \> 40 kg/m2) * Current user of Citrulline, Arginine, Nitric Oxide or other supplements known to affect nitric oxide synthesis (beet root juice or any beet supplement, Pycnogenol / Pine bark extract) * Known to be currently pregnant (self-disclosed)
Contact & Investigator
Ravinder Nagpal, PhD
PRINCIPAL INVESTIGATOR
Florida State University
Frequently Asked Questions
Who can join the NCT06588218 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Obesity and Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06588218 currently recruiting?
Yes, NCT06588218 is actively recruiting participants. Contact the research team at rnagpal@fsu.edu for enrollment information.
Where is the NCT06588218 trial being conducted?
This trial is being conducted at Tallahassee, United States.
Who is sponsoring the NCT06588218 clinical trial?
NCT06588218 is sponsored by Florida State University. The principal investigator is Ravinder Nagpal, PhD at Florida State University. The trial plans to enroll 36 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.